...
首页> 外文期刊>Cancer genetics >Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm
【24h】

Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm

机译:通过异体造血干细胞移植的扩大供体来源的del(20q)克隆的传播,而没有血液肿瘤的发展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Donor cell leukemia is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT), which may result from the development of a new malignancy in previously healthy donor cells after transplant into the recipient, or it may derive from the transmission of an occult leukemia from donor to recipient. We report a case of donor derived 20q11.2 deletion in a male patient who received an allogeneic HSCT from his HLA-identical sister for the treatment of his chronic lymphocytic leukemia. Bone marrow cells from the donor were found to contain the 20q deletion that expanded over time, but which was absent in her peripheral blood cells. Although cases of donor cell leukemia after HSCT have been reported, in this case there has been no evidence of an associated hematologic neoplasm in either the donor or recipient. Pre-transplant donor bone marrow evaluations are not practical or warranted, however the finding of new cytogenetic abnormalities after transplant mandates a thorough evaluation of the donor.
机译:供体细胞白血病是同种异体造血干细胞移植(HSCT)的罕见并发症,可能是由于原先健康的供体细胞在移植到受体中后出现新的恶性肿瘤,也可能是由于隐性白血病从捐献者。我们报告了一例从供体获得的20q11.2缺失的男性患者,该患者从他的HLA相同的姐妹接受了同种异体HSCT治疗他的慢性淋巴细胞性白血病。发现来自供体的骨髓细胞含有20q缺失,其随着时间的流逝而扩大,但在其外周血细胞中却不存在。尽管已经报道了HSCT后供体细胞白血病的病例,但是在这种情况下,没有证据表明供体或受体中都有相关的血液学肿瘤。移植前的捐献者骨髓评估是不切实际的,也不保证,但是,在移植后发现新的细胞遗传学异常要求对捐献者进行全面评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号